Zynex Inc. (ZYXI): Price and Financial Metrics
GET POWR RATINGS... FREE!
ZYXI POWR Grades
- ZYXI scores best on the Quality dimension, with a Quality rank ahead of 96.51% of US stocks.
- The strongest trend for ZYXI is in Growth, which has been heading down over the past 179 days.
- ZYXI ranks lowest in Stability; there it ranks in the 18th percentile.
ZYXI Stock Summary
- Of note is the ratio of ZYNEX INC's sales and general administrative expense to its total operating expenses; 86.45% of US stocks have a lower such ratio.
- With a year-over-year growth in debt of 55.11%, ZYNEX INC's debt growth rate surpasses 82.07% of about US stocks.
- Over the past twelve months, ZYXI has reported earnings growth of 308.64%, putting it ahead of 94.48% of US stocks in our set.
- If you're looking for stocks that are quantitatively similar to ZYNEX INC, a group of peers worth examining would be HZO, ARC, AVD, BOOT, and MOV.
- Visit ZYXI's SEC page to see the company's official filings. To visit the company's web site, go to www.zynex.com.
ZYXI Valuation Summary
- ZYXI's price/sales ratio is 2.4; this is 9.09% higher than that of the median Healthcare stock.
- Over the past 190 months, ZYXI's price/earnings ratio has gone up 16.2.
Below are key valuation metrics over time for ZYXI.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
ZYXI | 2022-09-01 | 2.4 | 5.1 | 17.7 | 13.5 |
ZYXI | 2022-08-31 | 2.4 | 5.0 | 17.4 | 13.3 |
ZYXI | 2022-08-30 | 2.4 | 4.9 | 17.1 | 13.1 |
ZYXI | 2022-08-29 | 2.4 | 5.0 | 17.6 | 13.5 |
ZYXI | 2022-08-26 | 2.5 | 5.1 | 18.0 | 13.8 |
ZYXI | 2022-08-25 | 2.5 | 5.2 | 18.2 | 13.9 |
ZYXI Growth Metrics
- The 5 year revenue growth rate now stands at 292.92%.
- The year over year revenue growth rate now stands at 54.18%.
- Its 3 year net cashflow from operations growth rate is now at 37.62%.

The table below shows ZYXI's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-06-30 | 142.994 | 12.805 | 19.724 |
2022-03-31 | 137.257 | 14.008 | 19.186 |
2021-12-31 | 130.301 | 6.949 | 17.103 |
2021-09-30 | 115.54 | -2.285 | 9.996 |
2021-06-30 | 100.78 | -6.743 | 5.222 |
2021-03-31 | 89.021 | -5.119 | 5.431 |
ZYXI's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ZYXI has a Quality Grade of A, ranking ahead of 95.17% of graded US stocks.
- ZYXI's asset turnover comes in at 1.459 -- ranking 6th of 186 Medical Equipment stocks.
- BLFS, MASI, and DXCM are the stocks whose asset turnover ratios are most correlated with ZYXI.
The table below shows ZYXI's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-09-30 | 1.459 | 0.778 | 0.274 |
2021-06-30 | 1.385 | 0.771 | 0.173 |
2021-03-31 | 1.459 | 0.776 | 0.254 |
2020-12-31 | 1.547 | 0.783 | 0.459 |
2020-09-30 | 1.683 | 0.788 | 0.648 |
2020-06-30 | 1.967 | 0.793 | 0.802 |
ZYXI Price Target
For more insight on analysts targets of ZYXI, see our ZYXI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $26.70 | Average Broker Recommendation | 1.5 (Moderate Buy) |
ZYXI Stock Price Chart Interactive Chart >
ZYXI Price/Volume Stats
Current price | $9.14 | 52-week high | $14.24 |
Prev. close | $9.17 | 52-week low | $4.97 |
Day low | $9.07 | Volume | 72,996 |
Day high | $9.34 | Avg. volume | 376,427 |
50-day MA | $8.57 | Dividend yield | N/A |
200-day MA | $7.89 | Market Cap | 351.07M |
Zynex Inc. (ZYXI) Company Bio
Zynex Inc., through its subsidiary, markets electro therapy products which help improve life of patients who have functional disabilities. The Company's products include muscle stimulation, inferential, and TENS devices. Zynex products are intended for home use for stroke rehabilitation, spinal cord injury rehabilitation, incontinence, and other applications.
Latest ZYXI News From Around the Web
Below are the latest news stories about ZYNEX INC that investors may wish to consider to help them evaluate ZYXI as an investment opportunity.
7 Hot Small-Cap Stocks to Buy in SeptemberIt's easier to make huge profits with hot small-cap stocks than with large-cap ones. |
Zynex Medical to Participate in H.C. Wainwright Annual Global Investment ConferenceZynex, Inc. (Nasdaq: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that the Company's management will participate virtually in the H.C. Wainwright Annual Global Investment Conference. Interested parties can access the webcast on the Events section of the website at https://zynexmed.investorroom.com/ir-home on Monday, September 12th, 2022, at 7am |
Zynex Medical to Participate in Inaugural Gilmartin Group Emerging Growth Company ShowcaseZynex, Inc. (Nasdaq: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that the Company's management will participate virtually in the Gilmartin Group Emerging Growth Company Showcase on August 31st, 2022 at 11:00 am ET. Interested parties can access the live and archived webcast at https://zynexmed.investorroom.com/ir-home. |
Zynex Announces First Enrollments in Apheresis Donation Clinical Trial with Second Generation Fluid Monitoring SystemZynex, Inc. (Nasdaq: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced it has started enrollments in an ongoing apheresis clinical trial with its second-generation fluid monitoring system, the CM-1600. |
Zynex Recognized in Top 100 Healthcare Technology Companies of 2022Zynex, Inc. (Nasdaq: ZYXI) an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced The Healthcare Technology Report has recognized Zynex as 33rd in the Top 100 Healthcare Technology Companies of 2022. |
ZYXI Price Returns
1-mo | -3.08% |
3-mo | 12.84% |
6-mo | 76.11% |
1-year | -22.06% |
3-year | 11.71% |
5-year | 458.54% |
YTD | 0.84% |
2021 | -25.93% |
2020 | 71.03% |
2019 | 167.69% |
2018 | -7.55% |
2017 | 960.10% |
Continue Researching ZYXI
Here are a few links from around the web to help you further your research on Zynex Inc's stock as an investment opportunity:Zynex Inc (ZYXI) Stock Price | Nasdaq
Zynex Inc (ZYXI) Stock Quote, History and News - Yahoo Finance
Zynex Inc (ZYXI) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...